C-reactive protein decreases prostacyclin release from human aortic endothelial cells.
BACKGROUND
In addition to being a risk marker for cardiovascular disease, much recent data suggest that C-reactive protein (CRP) promotes atherogenesis. Decreased endothelial NO and prostacyclin (PGI2) contribute to a proatherogenic and prothrombotic state. We have shown that CRP decreases endothelial NO synthase expression and bioactivity in human aortic endothelial cells (HAECs). PGI2 is a potent vasodilator and inhibitor of platelet aggregation. Hence, the aim of this study was to examine the effect of CRP on PGI2 release from HAECs and human coronary artery endothelial cells (HCAECs).


RESULTS
HAECs and HCAECs were incubated with human CRP (0 to 50 microg/mL for 24 hours). The release of PGF-1alpha, a stable product of PGI2, was also assayed in the absence and presence of a potent agonist, A23187. CRP significantly decreased PGF-1alpha release from HAECs under basal (48% decrease, P<0.001; n=5) and stimulated (26% decrease, P<0.01; n=5) conditions. CRP had no effect on PGI2 synthase (PGIS) mass. By increasing both superoxide and inducible NO synthase, CRP resulted in increased nitration of PGIS by peroxynitrite. The increased nitration and decreased activity of PGIS by CRP was reversed with peroxynitrite scavengers.


CONCLUSIONS
Thus, CRP decreases PGI2 release from HAECs by inactivating PGIS via nitration, additionally contributing to its atherogenicity.
D001011:Aorta / Q000166:cytology / Q000378:metabolism*; D001205:Ascorbic Acid / Q000494:pharmacology; D002097:C-Reactive Protein / Q000494:pharmacology*; D002478:Cells, Cultured; D003331:Coronary Vessels / Q000166:cytology / Q000378:metabolism; D003577:Cytochrome P-450 Enzyme System / Q000737:chemistry / Q000378:metabolism; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism*; D011464:Epoprostenol / Q000096:biosynthesis*; D016166:Free Radical Scavengers / Q000494:pharmacology; D006801:Humans; D019746:Intramolecular Oxidoreductases / Q000737:chemistry / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II; D030421:Peroxynitrous Acid / Q000378:metabolism; D011460:Prostaglandins F / Q000096:biosynthesis; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000032:analysis; D014527:Uric Acid / Q000494:pharmacology
D016166:Free Radical Scavengers; D011460:Prostaglandins F; D030421:Peroxynitrous Acid; D014527:Uric Acid; C002744:3-nitrotyrosine; D014443:Tyrosine; D002097:C-Reactive Protein; D003577:Cytochrome P-450 Enzyme System; D011464:Epoprostenol; C496319:NOS2 protein, human; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; D019746:Intramolecular Oxidoreductases; C022461:prostacyclin synthetase; D001205:Ascorbic Acid; C100006:prostaglandin F1